ArticleNature reviews. Nephrology2018
Adverse effects of SGLT2 inhibitors on bone health.
Registry-linked trialAbstract read
In one paragraph
Article in Nature reviews. Nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02891954. Cited by 33 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenomics to Predict Responses to SGLT2 Inhibitors
PMID 29669938PMID 31109940PMID 26086329PMID 25523498PMID 38947416PMID 38481375PMID 37738423other papers from this trial
Open the trial in the graphWho cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.BMC endocrine disorders · 2024Pooled it
- Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023Pooled it
- Effects of Dapagliflozin on the Bone of Patients with CKD on Dialysis.Calcified tissue international · 2026Trial
- Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial.Journal of diabetes · 2024 · on this mapTrial
- The effect of empagliflozin on renal outcomes compared to sitagliptin with type 2 diabetes: target trial emulation using electronic medical records.International journal of clinical pharmacy · 2026Article
- Bone from Healthy Individuals and Patients with CKD Expresses the Sodium-Glucose Co-transporter-2 (SGLT2).Calcified tissue international · 2026Article
- Association between SGLT2 inhibitor use and the risk of vertebral augmentation after initial osteoporotic vertebral fracture in patients with type 2 diabetes.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Article
- Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice.Journal of diabetes investigation · 2024Observational
- Fractures in women with type 2 diabetes are associated with marked deficits in cortical parameters and trabecular plates.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024Article
- Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of Incretines? A 12 Months Longitudinal Study.Calcified tissue international · 2024Article
- Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH.The Journal of clinical endocrinology and metabolism · 2024 · on this mapArticle
- Drug Safety Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Comorbid Patients by Review of Systemic Extraglycemic Effects.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Pharmacogenetics of sodium-glucose co-transporter-2 inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.Diabetes, obesity & metabolism · 2023Article
- Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients.World journal of transplantation · 2023Review
- Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse effects on 1,25-dihydroxyvitamin D and PTH.medRxiv : the preprint server for health sciences · 2023Article
- Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker.medRxiv : the preprint server for health sciences · 2023Article
- Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate.Innovations in pharmacy · 2023Article
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Jenny E BlauMetabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Simeon I TaylorDivision of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. staylor2@som.umaryland.edu.
Funding
Research BaseP30DK072488 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI MITCHELL, BRAXTON D, TAYLOR, SIMEON I. · 2005 to 2019
$17.3MHyperparathyroidism-- Etiology, Diagnosis And TreatmentZIADK043006 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JHA, SMITA · 2011 to 2025
$8.9MGenetics of Response to CanagliflozinR01DK118942 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI BEITELSHEES, AMBER L, TAYLOR, SIMEON I. · 2018 to 2022
$3.5MPharmacogenomics of SGLT2 inhibitors: Pilot & Feasibility StudyR21DK105401 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI TAYLOR, SIMEON I. · 2015 to 2016
$422kNIDDK NIH HHS P30 DK072488NIDDK NIH HHS R01 DK118942NIDDK NIH HHS R21 DK105401
Abstract
PubMed holds no abstract for this paper.
Indexed as
Bone Demineralization, PathologicBone DensityCanagliflozinFibroblast Growth Factor-23Fibroblast Growth FactorsFractures, BoneHumansParathyroid HormonePhosphorusSodium-Glucose Transporter 2 InhibitorsVitamin D1,25-dihydroxyvitamin DCanagliflozinFibroblast Growth Factor-23Fibroblast Growth FactorsParathyroid HormonePhosphorusSodium-Glucose Transporter 2 InhibitorsVitamin D
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02891954ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.